MX375916B - Composicion para prevenir o tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito. - Google Patents

Composicion para prevenir o tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.

Info

Publication number
MX375916B
MX375916B MX2016005006A MX2016005006A MX375916B MX 375916 B MX375916 B MX 375916B MX 2016005006 A MX2016005006 A MX 2016005006A MX 2016005006 A MX2016005006 A MX 2016005006A MX 375916 B MX375916 B MX 375916B
Authority
MX
Mexico
Prior art keywords
composition
isoforms
lateral sclerosis
amyotrophic lateral
preventing
Prior art date
Application number
MX2016005006A
Other languages
English (en)
Other versions
MX2016005006A (es
Inventor
Jae Gyun Jeong
Original Assignee
Helixmith Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helixmith Co Ltd filed Critical Helixmith Co Ltd
Priority claimed from PCT/KR2014/009971 external-priority patent/WO2015060650A2/ko
Publication of MX2016005006A publication Critical patent/MX2016005006A/es
Publication of MX375916B publication Critical patent/MX375916B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una composición para prevenir o tratar la esclerosis lateral amiotrófica, conteniendo la composición, como un ingrediente activo, dos o más isoformas de un factor de crecimiento de hepatocito (HGF) o un polinucleótido que codifica las isoformas. La composición de la presente invención se usa para prevenir o tratar efectivamente la esclerosis lateral amiotrófica.
MX2016005006A 2013-10-22 2014-10-22 Composicion para prevenir o tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito. MX375916B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130126216 2013-10-22
PCT/KR2014/009971 WO2015060650A2 (ko) 2013-10-22 2014-10-22 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물
KR1020140143377A KR101779775B1 (ko) 2013-10-22 2014-10-22 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
MX2016005006A MX2016005006A (es) 2016-07-14
MX375916B true MX375916B (es) 2025-03-07

Family

ID=53386224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005006A MX375916B (es) 2013-10-22 2014-10-22 Composicion para prevenir o tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.

Country Status (12)

Country Link
US (1) US10639351B2 (es)
EP (1) EP3061457B1 (es)
JP (1) JP6240337B2 (es)
KR (2) KR101779775B1 (es)
CN (1) CN105682676B (es)
AU (1) AU2014337870B2 (es)
BR (1) BR112016008267A2 (es)
CA (1) CA2926607C (es)
ES (1) ES2773305T3 (es)
MX (1) MX375916B (es)
RU (1) RU2639582C2 (es)
SG (1) SG11201602452SA (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046202B1 (fr) * 2015-12-24 2017-12-29 Snecma Turboreacteur avec un moyen de reprise de poussee sur le carter inter-compresseurs
RU2762367C1 (ru) * 2017-12-29 2021-12-20 Ньюромион Инк. Вектор на основе аденоассоциированного вируса (aav), имеющий гибридный ген hgf, введенный в него
CA3106085A1 (en) * 2018-07-17 2020-04-23 Helixmith Co., Ltd. Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
CN110577954A (zh) * 2019-10-12 2019-12-17 北京万福来生物技术有限责任公司 突变的肝细胞生长因子基因及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255320A3 (en) 1986-07-28 1989-09-06 Genzyme Corporation Production of proteins in myeloma cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2022752C (en) 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
DK0539590T3 (da) 1990-07-13 1999-10-11 Snow Brand Milk Products Co Ltd Plasmid indeholdende DNA, som koder for aminosyresekvensen af TCF-II, en transformeret celle og fremstilling af et fysiolog
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US7323297B1 (en) 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5652225A (en) 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US6143714A (en) 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
US20030148968A1 (en) 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AU6754496A (en) 1995-08-29 1997-03-19 Sumitomo Pharmaceuticals Company, Limited Medicine comprising hgf gene
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
KR20070005030A (ko) 1997-05-06 2007-01-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 혈관형성성 트랜스유전자의 생체내 송달에 의한 심장 질환및 심실 리모델링을 치료하기 위한 방법 및 조성물
WO1999036103A1 (en) 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
JPH11246433A (ja) 1998-03-03 1999-09-14 Sumitomo Pharmaceut Co Ltd 心筋梗塞治療剤
US20040228834A1 (en) 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
EP1061800A4 (en) 1998-03-09 2004-10-06 Caritas St Elizabeths Boston COMPOSITIONS AND METHODS FOR MODULATING THE VASCULARIZATION
IL138306A0 (en) 1998-03-13 2001-10-31 American Home Prod Polynucleotide composition, method of preparation and use thereof
EP1555033A3 (en) 1998-03-13 2005-08-17 Wyeth Polynucleotide composition, method of preparation, and use thereof
US7276359B1 (en) 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
AU5065599A (en) 1998-08-05 2000-02-28 Sumitomo Pharmaceuticals Company, Limited Preparations for the administration of hepatocyte growth factor
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
KR20010108053A (ko) 1999-10-29 2001-12-07 무라야마 마사노리 당뇨병성 허혈성 질환 유전자 치료
KR20020049031A (ko) 1999-11-05 2002-06-24 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 생체내 유전자 송달에 의하여 심혈관 질환을 치료하기위한 기술 및 조성물
WO2002000258A1 (en) 2000-06-27 2002-01-03 Anges Mg, Inc. Medicinal compositions for angiogenic therapy
CN1466463A (zh) 2000-09-13 2004-01-07 中外制药株式会社 缺血性疾病治疗剂
JP5442173B2 (ja) 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤
US20030176347A1 (en) 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
CN1150035C (zh) 2000-12-21 2004-05-19 中国人民解放军军事医学科学院放射医学研究所 一种重组质粒及其在疾病防治中的应用
EP1361896A2 (en) 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US7521187B2 (en) 2002-12-23 2009-04-21 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US20050164208A1 (en) 2004-01-22 2005-07-28 Paul Poulin Storage of genetic information
KR100833612B1 (ko) 2004-12-29 2008-05-30 에프씨비파미셀 주식회사 간엽 간세포로부터 분화된 신경세포를 유효성분으로함유하는 신경계 질환 치료용 약학 조성물
US20070059288A1 (en) 2005-03-31 2007-03-15 Dinsmore Jonathan H Treatment for heart disease
US20070212390A1 (en) 2005-09-22 2007-09-13 Ludwig Institute For Cancer Research Protease-resistant forms of VEGF-D, method of making and method of use
BRPI0618488A2 (pt) 2005-11-10 2011-08-30 Receptor Biologix Inc proteìnas de fusão de ìntron de fator de crescimento de hepatócito
WO2007132873A1 (ja) 2006-05-17 2007-11-22 Yoshiyuki Koyama 核酸、オリゴ核酸、又はその誘導体導入用の凍結乾燥体
WO2007142651A1 (en) 2006-06-09 2007-12-13 Caritas St. Elizabeth Medical Center Of Boston, Inc. Methods and compositions for the treatment of neuropathy
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
US8435953B2 (en) 2007-11-07 2013-05-07 Yasuhiko Tabata Sustained release composition containing SDF-1
US20090202606A1 (en) 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
BRPI0911511B8 (pt) 2008-04-09 2021-05-25 Helixmith Co Ltd formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo
RU2413524C1 (ru) 2009-07-31 2011-03-10 Общество с ограниченной ответственностью "КриоЦентр" Способ лечения психических и неврологических расстройств
CN102869776B (zh) 2009-12-23 2017-06-23 库尔纳公司 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
WO2012025925A1 (en) 2010-08-24 2012-03-01 Rappaport Family Institute For Research In The Medical Sciences Methods of improving transplantation using sdf-1alpha
WO2013037521A1 (en) 2011-09-16 2013-03-21 Medical Research Council Modified hgf-1k1 polypeptide
WO2013037520A1 (en) 2011-09-16 2013-03-21 Glaxo Group Limited Modified hgf-1k1 polypeptide
JP2013129661A (ja) * 2013-02-20 2013-07-04 Toshiichi Nakamura 筋萎縮性側索硬化症治療剤

Also Published As

Publication number Publication date
EP3061457B1 (en) 2020-01-22
RU2016119116A (ru) 2017-11-28
RU2639582C2 (ru) 2017-12-21
CA2926607A1 (en) 2015-04-30
MX2016005006A (es) 2016-07-14
HK1219873A1 (zh) 2017-04-21
JP6240337B2 (ja) 2017-11-29
BR112016008267A2 (pt) 2017-10-03
US10639351B2 (en) 2020-05-05
EP3061457A4 (en) 2017-06-07
KR20150047108A (ko) 2015-05-04
US20160250291A1 (en) 2016-09-01
ES2773305T3 (es) 2020-07-10
AU2014337870A1 (en) 2016-05-05
CA2926607C (en) 2018-10-23
AU2014337870B2 (en) 2019-11-28
KR101779775B1 (ko) 2017-09-21
KR101860452B1 (ko) 2018-05-24
KR20170104129A (ko) 2017-09-14
SG11201602452SA (en) 2016-05-30
EP3061457A2 (en) 2016-08-31
CN105682676A (zh) 2016-06-15
CN105682676B (zh) 2020-10-23
JP2016534149A (ja) 2016-11-04

Similar Documents

Publication Publication Date Title
MX373307B (es) Compuestos de biaril-amida como inhibidores de cinasa.
MX386598B (es) Compuestos antibacterianos.
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2016000106A1 (es) Sulfonamidas como moduladores de canales de sodio.
MX375674B (es) Compuestos de carboxamida inhibidores de la actividad de cinasa rip2.
BR112015032595A8 (pt) inibidores de ido
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
BR112016021648A2 (pt) novos compostos
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112016002524A2 (pt) alvos moleculares para a prevenção e/ou tratamento de fibrose, cicatrizes hipertróficas e quelóides
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
MX394452B (es) Inhibicion de la actividad de olig2.
MX375916B (es) Composicion para prevenir o tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.
MX378164B (es) Amidas aromaticas de acido carboxilico.
EA201691057A1 (ru) Новые способы лечения нейродегенеративных заболеваний
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201690594A1 (ru) Состав для лечения вич-инфекции на основе атазанавира и кобицистата
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
KR101501876B9 (ko) 자일리톨을 유효성분으로 함유하는 인플루엔자 바이러스 감염증 예방 또는 치료용 조성물
CL2015002188A1 (es) Agentes analgésicos oculares tópicos
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: HELIXMITH CO., LTD.

FG Grant or registration